The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Inhibition of FGFR4 increases oxaliplatin and 5-fluorouracil sensitivity in Kras wild-type and mutant colorectal cancer cells.
R. C. Turkington
No relevant relationships to disclose
W. L. Allen
No relevant relationships to disclose
L. Stevenson
No relevant relationships to disclose
V. Coyle
No relevant relationships to disclose
P. V. Jithesh
No relevant relationships to disclose
I. Proutski
No relevant relationships to disclose
C. Fenning
No relevant relationships to disclose
G. Stewart
No relevant relationships to disclose
S. Van Schaeybroeck
No relevant relationships to disclose
D. Longley
No relevant relationships to disclose
P. G. Johnston
Employment or Leadership Position - Almac Diagnostics
Consultant or Advisory Role - Chugai Pharma; Roche; Sanofi
Stock Ownership - Almac Diagnostics; Fusion Antibodies
Honoraria - AstraZeneca; Chugai Pharma; Pfizer; Roche; Sanofi
Research Funding - Amgen; AstraZeneca